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Background: While older adults (age 75 and over) represent a large and growing proportion of patients with acute
myocardial infarction (AMI), they have traditionally been under-represented in cardiovascular studies. Although
chronological age confers an increased risk for adverse outcomes, our current understanding of the heterogeneity
of this risk is limited. The Comprehensive Evaluation of Risk Factors in Older Patients with AMI (SILVER-AMI) study
was designed to address this gap in knowledge by evaluating risk factors (including geriatric impairments, such as
muscle weakness and cognitive impairments) for hospital readmission, mortality, and health status decline among
older adults hospitalized for AMI.
Methods/Design: SILVER-AMI is a prospective cohort study that is enrolling 3000 older adults hospitalized for
AMI from a recruitment network of approximately 70 community and academic hospitals across the United States.
Participants undergo a comprehensive in-hospital assessment that includes clinical characteristics, geriatric
impairments, and health status measures. Detailed medical record abstraction complements the assessment with
diagnostic study results, in-hospital procedures, and medications. Participants are subsequently followed for six
months to determine hospital readmission, mortality, and health status decline. Multivariable regression will be used
to develop risk models for these three outcomes.
Discussion: SILVER-AMI will fill critical gaps in our understanding of AMI in older patients. By incorporating geriatric
impairments into our understanding of post-AMI outcomes, we aim to create a more personalized assessment of
risk and identify potential targets for interventions.
Trial registration: Trial registration number: NCT01755052.
Keywords: Acute myocardial infarction, Aging, Hospital readmission, Health statusBackground
Among patients hospitalized for acute myocardial infarc-
tion (AMI), one-third are 75 years or older [1]. The num-
ber of incident AMI cases in this age group is expected to
double over the next 30 years as the mean age of the gen-
eral population increases [2], yet this group has been
under-represented in AMI clinical trials and epidemio-
logic studies [3]. This group is fundamentally different
from younger patients with AMI: they have a higher* Correspondence: Sarwat.Chaudhry@yale.edu
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unless otherwise stated.burden of comorbid diseases and aging-related physical
and cognitive impairments, as well as lower physiologic
reserve. Results from studies of younger patients with
AMI may therefore not be directly applicable to this grow-
ing population.
While advanced age is a risk factor for adverse out-
comes after AMI [1], there is great heterogeneity among
older patients and chronological age is a relatively crude
indicator of physiological age [3,4]. Despite emerging
interest in understanding the role of geriatric conditions
(such as physical and cognitive impairments) as they
pertain to cardiovascular outcomes [3], the majority of
studies examining risk have used administrative datasetsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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available risk stratification tools for AMI incorporate geriatric
conditions. Furthermore, these risk models have only modest
discrimination in older patients [6,7], and were designed
solely to predict clinical events (i.e., mortality, reinfarction)
rather than patient-centered outcomes, such as health status.
The Comprehensive Evaluation of Risk Factors in
Older Patients with AMI (SILVER-AMI, R01HL115295,
PI Chaudhry) study was designed to address these know-
ledge gaps by melding principles from geriatrics and car-
diology with the goal of more precisely characterizing
the risk of traditional clinical events, as well as patient-
centered outcomes, in older adults with AMI. The pri-
mary objective is to generate risk models that predict
all-cause readmission, all-cause mortality, and decline in
health status, that exceed the capabilities of currently
available risk models in older adults. We hypothesize
that the incorporation of geriatric conditions will lead to
better discrimination than existing risk models. Secondary
objectives are to: (1) estimate the frequency and determi-
nants of adverse post-hospital events important in this
population, including medication side effects, symptoms,
falls, and bleeding; and (2) describe AMI processes of care
(e.g. door-to-balloon time, revascularization strategies, use
of secondary prevention medications). We believe that
achieving these objectives can inform complex post-AMI
decision-making in older adults (Figure 1). The purpose
of this article is to describe the design, rationale, and
methods of the SILVER-AMI study.
Methods/Design
SILVER-AMI is a multi-center, longitudinal cohort study
in which participants undergo a comprehensive baseline
(in-hospital) assessment, and then complete a follow-up
telephone interview (six months after discharge). TheFigure 1 Comprehensive assessment to inform post-AMI decision ma
medical decision-making. (For clarity, not all possible risk factors or post-AMstudy received approval from the Yale Institutional Review
Board (IRB), as well as IRBs at the participating study sites,
and is registered at www.clinicaltrials.gov (NCT01755052,
registered 11/27/2012).
Study sites: management and training
The recruitment network for SILVER-AMI was assem-
bled with the goal of reflecting a wide geographic distri-
bution and a diverse mix of practice types. There are
approximately 70 recruitment sites located in the United
States representing 27 states (Figure 2). The SILVER-AMI
network is built upon the foundation of the recruitment
network assembled for the VIRGO study [8] and additional
sites were recruited through the American College of
Cardiology’s Section of Geriatric Cardiology. The majority
of sites (71.4%) are non-academic hospitals. Hospitals are
heterogeneous in size (range: 83 to 2292 beds, median 475)
and location (urban: 47.1%, suburban/rural: 52.9%).
Each site identifies a site research coordinator who has
primary responsibility for implementing the study proto-
col. Prior to study initiation, the site research coordinators
complete required trainings (in the recruitment of older
hospitalized patients, obtaining of informed consent, and
use of the electronic data capture system) conducted by
the Yale Coordinating Center, and are supplied with stan-
dardized equipment to perform the physical assessments.
Patient screening and determination of eligibility
Screening is performed in the hospital setting by the site
research coordinators who review daily admission records
to identify potentially eligible participants. Site research
coordinators then perform a medical record review to
confirm eligibility in accordance with the criteria found in
the Third Universal Definition of Myocardial Infarction
[9], listed in Table 1.king in older adults. Assessment of multiple domains may optimize
I clinical decisions are listed).
Figure 2 SILVER-AMI national recruitment network.
Dodson et al. BMC Health Services Research 2014, 14:506 Page 3 of 9
http://www.biomedcentral.com/1472-6963/14/506If, during the screening process, the site research coord-
inator is concerned about the potential participant’s deci-
sional capacity, the University of California, San Diego
Brief Assessment of Capacity to Consent (UBACC) is
administered [10]. If potential participants demonstrate
impaired decision-making ability based on the UBACC,
proxy consent is obtained in compliance with local regula-
tions for legally authorized representatives.
In order to confirm study eligibility and provide fur-
ther classification, medical records from enrolled partici-
pants are adjudicated by two physician investigators (JD,
SC) at the Yale Coordinating Center, who confirm the
baseline AMI diagnosis, interpret the diagnostic electro-
cardiogram (ECG), and determine whether the event
represents ST elevation myocardial infarction (STEMI)
or non ST elevation myocardial infarction (NSTEMI)
based on previously published criteria [9].Table 1 Eligibility Criteria for SILVER-AMI
Inclusion criteria
Age ≥75 years
Diagnosis of acute myocardial infarction
- Serum troponin I or troponin T elevation above laboratory’s upper
limit of normal, and either (1) ischemic ECG findings, (2) anginal
symptoms, (3) imaging evidence of new loss of viable myocardium
or new regional wall motion abnormality; (4) identification of an
intracoronary thrombus on angiographya
aIn accordance with Universal Definition of Myocardial Infarction [14].In-hospital assessment
Participants undergo an interview and physical assessment
by the site research coordinator during their baseline AMI
hospitalization (Table 2). In addition to sociodemographic
and presentation characteristics, specific domains are tested
which are described below. Participants receive a $25 gift
card for completing this assessment.
Health status measures, symptom burden, and psychosocial
assessments
Participants are asked about health status with the Short
Form 12 (SF-12) [11], a widely used health status meas-
ure that has demonstrated reliability and validity in
many populations, including older adults. In addition,
dimensions of health status specific to coronary artery
disease are assessed with the abbreviated Seattle Angina
Questionnaire (SAQ) [12] which measures three angina-Exclusion criteria
Initial troponin elevation occurs >24 hours after hospital admission
Acute myocardial infarction secondary to inpatient procedure or surgery
Transferred from another hospital with a length of stay >24 hours at the
referring hospital
Incarcerated
Unable to provide informed consent with no proxy available

















Procedures (cardiac catheterization, PCI, CABG,
pacemaker, ICD)
x x




Health status measures, symptom burden, psychosocial
assessments
General health (SF-12) x x
CAD-specific health (SAQ-7) x x
General symptoms (ESAS) x x
Social support (MOS-SSS) x
Comprehensive geriatric assessment
Depressive symptoms (PHQ-8) x x
Cognition (TICS, COWAT) x
Vision and hearing x
Grip strength (dynamometer) x
Functional mobility (TGG) x
Activities of Daily Living x x
Fall assessment x x
Delirium (abbreviated CAM) x x
Orthostatic vital signs x
Alcohol and tobacco frequency x
Post-discharge health care utilization
Emergency Department visits x
Hospital readmissions x
Cardiac procedures x
Medication adverse effects x
Medication adherence x
Deaths x
Abbreviations: PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, ICD implantable cardioverter defibrillator, SF-12 Short-Form 12,
CAD coronary artery disease, SAQ-7 abbreviated Seattle Angina Questionnaire, ESAS Edmonton Symptom Assessment Scale, MOS-SSS Medical Outcomes Study
Social Support Scale, PHQ-8 Patient Health Questionnaire, TICS Modified Telephone Interview for Cognitive Status, COWAT Controlled Word Association Test,
TGG Timed Get Up and Go, CAM Confusion Assessment Method.
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and quality of life.
Symptoms are assessed with the Edmonton Symptom
Assessment Scale (ESAS) [13], a visual analogue scale that
contains nine common symptoms (pain, fatigue, nausea,depression, anxiety, drowsiness, appetite, well-being, short-
ness of breath) that are rated by participants on a severity
scale of 1 (no symptoms) to 10 (worst possible symptoms).
Depression is known to be prognostically important in
patients with cardiovascular disease; [14] we therefore
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Health Questionnaire (PHQ-8) [15]. In addition, a short-
ened five-item version of the Medical Outcomes Study
Social Support Scale (MOS-SSS) evaluates perceived so-
cial support [16].
Geriatric conditions
General cognitive function is evaluated with the Telephone
Interview of Cognitive Status (TICS) [17]. We chose the
TICS because it can be administered in <10 minutes, can
be used to detect mild as well as severe cognitive impair-
ments, does not require writing (i.e. can be used despite
visual or motor impairments), and can be converted to a
Mini Mental State Examination (MMSE) equivalent [18].
In addition to general cognitive function, we include an as-
sessment of executive function, which is relevant for spe-
cific tasks such as adherence to complex medical regimens
after discharge, with the Controlled Word Association Test
(COWAT) [19].
Vision questions are adapted from the Visual Function-
ing Questionnaire (VFQ-25); [20] participants are asked
to rate their general vision on an ordinal scale (from “ex-
cellent” to “very poor”), and to indicate whether they have
difficulty reading print or doing work or hobbies. Hearing
is assessed with a global question (“do you have a hearing
problem now?”) that has shown good sensitivity and speci-
ficity compared with audiography [21].
Muscle strength and functional mobility are important
predictors of future disability and health status decline
[22,23]. For muscle strength we chose to measure grip
strength, which is assessed by the participant using their
dominant hand to squeeze a handheld dynamometer
(B&L Engineering, Santa Ana, CA); results are recorded
in kilograms (kg) for three successive attempts. Func-
tional mobility is measured with the Timed Get Up and
Go (TUG) test [23], which requires the participant to
rise from a seated position, walk 3 meters, and then return
to the chair and sit down. The time it takes to complete
this test in seconds is recorded, as well as a subjective rat-
ing of the person’s movements on a scale of 1–5 from nor-
mal to severely abnormal.
Activities of Daily Living (ADLs) [24] are measured
with four interview items that assess whether partici-
pants are able to perform, without help from another
person, the tasks of bathing, dressing, getting out of a
chair, and ambulating. Participants are also asked how
many falls they have had in the past year (from none
to ≥ four).
Medical record abstraction
To complement the participant interview and assessment,
an in-depth medical record review is performed by the site
research coordinator who collects information about clin-
ical status at the time of the initial presentation (bloodpressure, heart rate, presence of decompensated heart fail-
ure), comorbidities, laboratory results, in-hospital adverse
events, and discharge disposition (Figure 3). Medical re-
cords are also provided to the Yale Coordinating Center
where a research nurse (NL) conducts an in-depth review
to collect information about medications, cardiac proce-
dures, and discharge instructions.
Six-month interview
The six-month telephone interview is conducted by staff
at the Yale Coordinating Center. For participants with
impaired decisional capacity at baseline, the six-month
interview is completed with both the participant and
assigned proxy.
The six-month interview repeats several key compo-
nents of the baseline interview (Table 2), including ques-
tions about both general and disease-specific health status.
In addition to the outcomes of re-admission and death,
we define a decline in health status as a 10% reduction in
overall quality of life as measured by the SF-12 [25]. Par-
ticipants are also questioned on whether they have been
re-hospitalized, and whether they have experienced any
signs or symptoms that they attribute to medications (i.e.,
“adverse effects”) since their AMI discharge. If present,
the participant is asked the medication to which they attri-
bute the symptoms and if any action was taken to address
the adverse effect. Participants receive an additional $50
gift card for completing the six-month interview.
Events review
At the six-month time point, the site research coordinator
collects medical records on any hospital readmissions, out-
patient cardiac procedures, emergency department (ED)
visits, and deaths from the index hospital, as well as all
other hospitals the participant reported using at the time
of baseline interview. Medical records are provided to the
Yale Coordinating Center where the events are reconciled
with the participant’s self-reported hospitalizations during
the 6-month phone interview. Any outstanding records are
then collected. Medical records and death certificates
are reviewed by physician investigators to determine
whether the reported events represent true hospital ad-
missions, as well as the primary discharge diagnosis,
and/or cause of death.
Data management
The baseline interview is completed by the site research
coordinator and transmitted electronically to the Yale
Coordinating Center within three days (Figure 3). A Yale
research assistant reviews the form and queries the site
for missing or incomplete items. The site also transmits
medical records, including emergency department and
inpatient notes, ECGs, cardiac catheterization and op-
erative (CABG) reports, and echocardiogram results, for
Figure 3 Procedures for data collection and management in the SILVER-AMI study. Data collection and management involves a
coordinated effort between study sites and Yale Coordinating Center.
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All study data are managed at the Yale Coordinating
Center using REDCap, an NIH-supported, HIPAA-
compliant web-based Electronic Data Capture (EDC)
system [26]. A custom Site Portal website manages the
various administrative and scientific site workflows, in-
cluding: site enrollment, IRB tracking; study document
distribution, staff training, participant enrollment, in-
voicing, and site performance monitoring. In addition,
we have integrated REDCap’s error detection and reso-
lution features into a Data Query Quality Control sys-
tem (DQCQ) that allows for error checks of varying
complexity using SAS programs.
Statistical analysis
The primary outcomes of SILVER-AMI are the occur-
rence of all-cause hospital readmission, all-cause death,
and decline in health status within six months of hospital
discharge. Using independent risk factors that include
cardio-centric factors (e.g. STEMI vs. NSTEMI, systolicblood pressure, Killip Class), as well as geriatric impair-
ments, we will construct risk stratification models that
predict the probability of each outcome for specific com-
binations of the risk factors. These models will be variants
of the Cox regression models for the time-to-event out-
comes (hospital readmission and mortality) and the logis-
tic model used for decline in health status. Because
mortality serves as a competing risk for hospital readmis-
sion, we will evaluate the associations of explanatory
variables with both time-to-event outcomes using the
competing risk approach of Fine and Gray [27]. All linear-
ity assumptions will be checked graphically and deviations
from model additivity will be accommodated by an exam-
ination of all statistically significant, clinically indicated
two-factor interactions. All missing data will be examined
for the nature of missingness, i.e., whether missing at ran-
dom, and if justifiable, multiple imputation will be applied.
Models will be evaluated with an examination of residuals
and goodness-of-fit statistics using SAS/STAT ® V9.3 (SAS
Institute, Cary, NC) or later, with statistical significance
defined as a two-sided p-value <0.05.
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be used to test the reproducibility of the risk stratifica-
tion tools. For internal validation, jackknife methods
[28] will be used to evaluate the percent of correct clas-
sification; external validation will be performed on the
500 randomly selected participants who were excluded
from both model building and internal validation.
Once the final models have been developed, user-
interface applications will be developed for “smart-phones”
and other hand-held devices. The model coefficients for
each outcome will be stored in hand-held applications
whose outputs will provide the probability of each out-
come. The inputs to the applications will consist of simple
yes/no entries denoting the presence or absence of risk
factors. Calculation will be presented in real time, and the
results will list specific risk factors, and probability of the
outcomes.
Sample size and power
Of the SILVER-AMI cohort of 3000 participants, 2500
participants will serve as the development cohort and
500 will be randomly selected as the validation cohort.
Based on 2008 Medicare data, we posited outcome rates
of 39% and 28% for all-cause readmission and mortality.
Based on previous research [29], we also assumed that a
10% decline in health status, as measured by the SF-36,
would occur in 35% of surviving participants. With re-
gard to the explanatory variables of primary interest, i.e.,
geriatric conditions and socio-demographic and clinical
factors, we assumed each would exhibit measures of rela-
tive risk ≥1.3 for each time-to-event outcome and ≥1.5 for
decline in health status. The 2500 participants in the de-
velopment cohort provide 90% power to detect the stated
magnitudes of relative risk for prevalence of the explana-
tory variables between 30% and 50%. For the validation
sample, the accepted standard for time-to-event and logis-
tic models should be large enough to contain a minimum
of 100 outcome events [30]. For mortality, the least fre-
quently expected outcome, the additional sample of 500
should allow for 140 events. The validation size of 500 will
be preserved regardless of overall mortality and dropout.
Discussion
SILVER-AMI will fill critical gaps in our understanding
of AMI in older patients. Using a large, diverse cohort of
older patients cared for in a variety of community-based
and academic settings, we will evaluate determinants of
post AMI risk (for readmission, mortality, and health
status decline). Secondarily, we will describe patterns of
adverse post-hospital events such as falls, bleeding, and
medication adverse effects.
The SILVER-AMI cohort builds on a long tradition of
NHLBI-funded longitudinal cohort studies that have de-
scribed care patterns and optimal management strategiesin patients with AMI [31-33]. Several unique aspects of
our study will extend knowledge beyond that provided
in earlier cohorts. First, our study uses a comprehensive
geriatric assessment, which includes an evaluation of an
individual’s cognition, muscle strength, physical function,
depressive symptoms, and falls history. While this assess-
ment has been increasingly incorporated into the care of
patients with cancer and has been shown to enhance pre-
diction of outcomes [34], its use in the care of patients
with cardiovascular disease is still uncommon. In addition
to creating a more personalized assessment of risk, the
geriatric assessment may identify specific impairments
that can serve as targets for interventions. For example,
patients with cognitive impairments can receive extra
assistance with managing medications and follow-up
appointments; in patients at high risk for medication
side effects, caution may be needed when considering
long-term dual antiplatelet therapy, oral anticoagulants,
or beta blockers.
A second unique feature of SILVER AMI involves the
incorporation of patient-centered outcomes not available
in most prior AMI registries, including symptoms, health
status, angina-specific quality of life, and adverse effects
from cardiovascular medications. Studies repeatedly show
that older patients may value these outcomes in decision-
making more importantly than simply prolonging life [35].
It is therefore important to understand health status in
the context of AMI, as well as which patients achieve
measurable improvement in health status after interven-
tions, such as PCI and CABG.
Third, there are several specific products that will be
developed from the data collected in SILVER-AMI. These
include separate risk models for three outcomes (readmis-
sion, mortality, and decline in health status) that, once cre-
ated, will be adapted for PC-based and smartphone use,
similar to the Framingham Risk Calculator [36] or TIMI
Risk Score [37]. Such decision aids may help to identify
patients in need of resource intensive post-hospital inter-
ventions and therefore lead to improvements in real-time
decision making at the point of care.
Finally, the recruitment network for SILVER-AMI in-
cludes approximately 70 sites across the U.S. in a variety
of geographic settings. The network involves a large
range of hospital sizes, as well as a mixture of academic
and community hospitals, ensuring a diverse mixture of
patients and practice patterns that will lend external val-
idity to our findings. This network also has the potential
to be used in future epidemiologic studies of other car-
diac conditions, or for trials of interventions aimed at
improving outcomes among older adults.
Conclusions
With the aging of the population, it is imperative to
identify determinants of post-AMI outcomes in older
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terns in the care of this population. Subsequently, the
knowledge gained from the SILVER-AMI cohort may be
used to design interventions directed at reducing hos-
pital readmission and mortality and improving health
status.
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